SRR607445
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.549
- IL6_JAK_STAT3_SIGNALING+0.540
- INFLAMMATORY_RESPONSE+0.519
- INTERFERON_GAMMA_RESPONSE+0.467
- ANGIOGENESIS+0.426
- INTERFERON_ALPHA_RESPONSE+0.414
- KRAS_SIGNALING_UP+0.411
- KRAS_SIGNALING_DN+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.363
- COMPLEMENT+0.342
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.629
- MYC_TARGETS_V2-0.563
- DNA_REPAIR-0.504
- ADIPOGENESIS-0.473
- MYC_TARGETS_V1-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.453
- FATTY_ACID_METABOLISM-0.416
- PROTEIN_SECRETION-0.415
- CHOLESTEROL_HOMEOSTASIS-0.362
- MTORC1_SIGNALING-0.359
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1335446 | GTEX | — | 0.975 |
| 2 | SRR1358561 | GTEX | — | 0.970 |
| 3 | SRR599510 | GTEX | — | 0.966 |
| 4 | SRR608598 | GTEX | — | 0.961 |
| 5 | SRR598894 | GTEX | — | 0.957 |
| 6 | SRR603658 | GTEX | — | 0.954 |
| 7 | SRR821602 | GTEX | — | 0.953 |
| 8 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.953 |
| 9 | SRR602131 | GTEX | — | 0.943 |
| 10 | SRR1077405 | GTEX | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.549 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.519 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.467 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.426 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.414 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.411 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.370 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.363 | Inavolisib | — uncovered |
| COMPLEMENT | 0.342 | Inavolisib | — uncovered |
| COAGULATION | 0.339 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.242 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.233 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.117 | Inavolisib | — uncovered |
| APOPTOSIS | 0.109 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.051 | Idelalisib | — uncovered |
| HYPOXIA | 0.048 | Idelalisib | — uncovered |